Evidence map›Paper›PMID 28717855›Full record

Trial reportInternational journal of clinical oncology2017

Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).

Tatsuya Okuno, Masashi Wakabayashi, Ken Kato, Masayuki Shinoda, Hiroshi Katayama, Hiroyasu Igaki, Yasuhiro Tsubosa, Takashi Kojima, Hiroshi Okabe, Yusuke Kimura and 10 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Nutritional management during chemotherapy and chemoradiotherapy for advanced esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tatsuya OkunoDivision of Gastroenterology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, 7-5-1 Kusunoki Chuo, Kobe, 650-0017, Japan. t-okuno@pg7.so-net.ne.jp.ORCID http://orcid.org/0000-0002-5450-8841
Masashi WakabayashiJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo, Japan.
Ken KatoGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Masayuki ShinodaDepartment of Gastrointestinal Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Hiroshi KatayamaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo, Japan.
Hiroyasu IgakiEsophageal Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Yasuhiro TsubosaDivision of Esophageal Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Takashi KojimaGastrointestinal Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan.
Hiroshi OkabeDepartment of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yusuke KimuraDepartment of Surgery, Iwate Medical University School of Medicine, Morioka, Japan.
Tatsuyuki KawanoTokyo Medical and Dental University, Tokyo, Japan.
Shinichi KosugiDepartment of Surgery, Niigata University Medical and Dental Hospital, Niigata, Japan.
Yasushi TohDepartment of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
Hoichi KatoEsophageal Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Kenichi NakamuraJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo, Japan.
Haruhiko FukudaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo, Japan.
Satoshi IshikuraDepartment of Radiology, Koshigaya Municipal Hospital, Koshigaya, Saitama, Japan.
Nobutoshi AndoDepartment of Surgery, International Goodwill Hospital, Yokohama, Japan.
Yuko KitagawaDepartment of Surgery, Keio University, School of Medicine, Tokyo, Japan.
Japan Esophageal Oncology Group/Japan Clinical Oncology Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to investigate the possible prognostic factors and predictive accuracy of the Glasgow Prognostic Score (GPS) for patients with unresectable locally advanced esophageal squamous cell carcinoma (LAESCC) treated with chemoradiotherapy.

methodsOne hundred forty-two patients were enrolled in JCOG0303 and assigned to the standard cisplatin and 5-fluorouracil (PF)-radiotherapy (RT) group or the low-dose PF-RT group. One hundred thirty-one patients with sufficient data were included in this analysis. A Cox regression model was used to analyze the prognostic factors of patients with unresectable LAESCC treated with PF-RT. The GPS was classified based on the baseline C-reactive protein (CRP) and serum albumin levels. Patients with CRP ≤1.0 mg/dL and albumin ≥3.5 g/dL were classified as GPS0. If only CRP was increased or only albumin was decreased, the patients were classified as GPS1, and the patients with CRP >1.0 mg/dL and albumin <3.5 g/dL were classified as GPS2.

resultsThe patients' backgrounds were as follows: median age (range), 62 (37-75); male/female, 119/12; ECOG PS 0/1/2, 64/65/2; and clinical stage (UICC 5th) IIB/III/IVA/IVB, 3/75/22/31. Multivariable analyses indicated only esophageal stenosis as a common factor for poor prognosis. In addition, overall survival tended to decrease according to the GPS subgroups (median survival time (months): GPS0/GPS1/GPS2 16.1/14.9/8.7).

conclusionsEsophageal stenosis was identified as a candidate stratification factor for randomized trials of unresectable LAESCC patients. Furthermore, GPS represents a prognostic factor for LAESCC patients treated with chemoradiotherapy. CLINICAL TRIAL INFORMATION: UMIN000000861.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellChemoradiotherapyCisplatinC-Reactive ProteinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophageal StenosisFemaleFluorouracilGlasgow Outcome ScaleHumansMaleMiddle AgedCisplatinC-Reactive ProteinFluorouracilChemoradiotherapyEsophageal stenosisGlasgow Prognostic ScorePrognostic factorT4 esophageal cancer

Identifiers

PMID28717855
PMCPMC5676839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.